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Other Suplementary Materials for this manuscript includes the following:  
Databases S1 to S10 as zipped archives: 
 
Database S1: Phenotypes for each case proband, including cardiac, neurodevelopmental disorders 
and extra-cardiac congenital anomalies. 
Database S2: List of de novo Mutations in CHD case cohort. 
Database S3: List of de novo Mutations in Control cohort. 
Database S4: List of de novo probabilities for each variant class in each protein-coding gene on 
the Nimblegen V2 exome, adjusted for depth in Cases. 
Database S5: List of de novo probabilities for each variant class in each protein-coding gene on 
the Nimblegen V2 exome, adjusted for depth in Controls. 
Database S6: Functional term enrichment analysis of all Genes with Damaging (loss of function + 
deleterious missense) de novo mutations in all cases.  
Database S7: Functional term enrichment analysis of all Genes with Loss of Function de novo 
mutations in 860 new cases.  
Database S8: List of 1,563 variants (1,161 unique genes) with damaging de novo mutations from 
7 independent NDD cohorts. 
Database S9: Functional term enrichment analysis among 69 genes with Damaging de novo 
mutations overlapping between CHD cases and the published NDD (P-NDD) cohort. 
Database S10: Percentile ranks of genes by expression in the developing mouse heart and brain. 
 
 
Abbreviations and Conventions used in this Supplement 
 
HHE: High Heart Expressed genes (genes in the top quartile of expression)! 
LHE: Lower Heart Expressed genes (genes in the bottom three quartiles of expression) 
HBE: High Brain Expressed genes (genes in the top quartile of expression) ! 
LBE: Lower Brain Expressed genes (genes in the bottom three quartiles of expression) 
LoF: Loss of function! 
D-Mis: Deleterious missense variants as predicted by Meta-SVM ! 
NDD: Neurodevelopmental disorders ! 
CA: Congenital Anomaly (extra-cardiac) 
!Bold face in tables: OR or Enrichments > 2; p < 0.005 
 
Materials and Methods 
 
Patient cohorts 
Pediatric Cardiac Genomics Consortium (PCGC): 
Probands were recruited from 10 centers in the United States and United Kingdom 
(Congenital Heart Disease Genetic Network Study of the PCGC) (4). The protocol was 
approved by the Institutional Review Boards of Boston Children’s Hospital, Brigham and 
Women’s Hospital, Great Ormond St. Hospital, Children’s Hospital of Los Angeles, 
Children’s Hospital of Philadelphia, Columbia University Medical Center, Icahn School 
of Medicine at Mount Sinai, Rochester School of Medicine and Dentistry, Steven and 
Alexandra Cohen Children’s Medical Center of New York, and Yale School of Medicine. 
Written informed consent was obtained from participating subjects or their parents. 
Probands without any first-degree relative with CHD were selected. Cardiac diagnoses 
were obtained from review of echocardiogram, catheterization and operative reports. 
Extra-cardiac congenital anomalies were determined from review of medical records. 
Determination of neurodevelopmental status was based on parental report when the 
proband was at least 12 months of age (answering “Yes” to the presence of at least one of 
the following conditions: developmental delay, learning disability, mental retardation, or 
autism).  
 
Pediatric Heart Network: 
Samples were selected from the DNA biorepository of the Single Ventricle 
Reconstruction (SVR) trial (5). In this trial, subjects underwent in-person 
neurodevelopmental testing at age 14 months with the Psychomotor Development Index 
(PDI) and Mental Development Index (MDI) of the Bayley Scales of Infant 
Development-II (24). In addition, subjects were evaluated with the Ages and Stages 
Questionnaire (ASQ), from which scores at age 3 years were analyzed (24). Probands 
were defined as having NDD if they had a PDI or MDI score of <70, or an “at risk” score 
in at least one of the five domains of the ASQ at 3 years. Blood or sputum samples for 








Control trios were kindly provided by the Simons Foundation Autism Research Initiative 
Simplex Collection. Simplex families (two unaffected parents, one child with autism 
spectrum disorder, and one unaffected sibling) underwent whole exome sequencing (7-9). 
Trios of unaffected family members served as controls for our study.  
 
Cardiac Phenotypes 
Cardiac phenotypes were divided into 5 major categories (Table S1) on basis of the major 
cardiac lesion: conotruncal defects (CTD, n=425), left ventricular outflow tract 
obstruction (LVO, n=426), heterotaxy (HTX, n=195), Other (n=131), Complex (n=36). 
CTD phenotypes include tetralogy of Fallot, D-loop transposition of the great arteries, 
double-outlet right ventricle, truncus arteriosus, ventricular septal defects, and aortic arch 
abnormalities. LVO phenotypes include hypoplastic left heart syndrome, coarctation of 
the aorta, and aortic stenosis/bicuspid aortic valve. HTX syndromes include left-right 
isomerism as the major malformation, and may include other defects such as 
transposition of the great arteries, atrioventricular canal defects, anomalous pulmonary 
venous drainage, and double outlet right ventricle. Isomerism of other organs was not 
considered a separate extra-cardiac CA for this study. Lesions in the “other” category 
include pulmonary valve abnormalities, anomalous pulmonary venous drainage, atrial 




Case trios were sequenced at the Yale Center for Genome Analysis as described 
previously (6). Genomic DNA from whole blood was captured with the NimbleGen v2.0 
exome capture reagent (Roche) and sequenced (Illumina HiSeq 2000, 75 base paired-end 
reads). Sequence data from control subjects were analyzed.  These samples were captured 
and sequenced using the same methods (59% at Yale School of Medicine, 38% at Cold 
Spring Harbor, 3% at Washington University in St. Louis). Sequencing metrics are 
provided in Table S12. Reads were processed via three independent analysis pipelines at 
Harvard Medical School and Yale School of Medicine, and Columbia University Medical 
Center. At Harvard, reads were mapped to the human reference genome hg19 with 
Novoalign (www.novocraft.com) and processed according to the best practices of the 
Genome Analysis Toolkit 3.0 (25). Variant calls were made with GATK HaplotypeCaller 
and annotated with Meta-SVM (11) and other annotations using dbNSFP (26). At 
Columbia, reads were mapped to hg19 using BWA-mem (27). At Yale, reads were 
mapped to the human reference hg19 with BWA-mem and variants were called using 
SAMtools. Variants were annotated with an in-house pipeline and de novo mutations 
were called using a Bayesian algorithm as previously described (6).  Exome sequence 
data for case trios are deposited in dbGaP (accession phs000571.v2.p1). 
 
Identification of de novo mutations 
A high stringency method for selecting de novo mutations was used because DNA from 
controls subjects (recruited by the Simons Foundation Autism Research Initiative) was 
not available for confirmation by Sanger sequencing. Rare (AF < 0.04%) on-target 
heterozygous SNVs or indels were initially identified based on presence in the child and 
 
 
absence in the parents. Candidate de novo mutations were pooled from all three pipelines 
and then further filtered based on depth (minimum 10 reads total and 5 alternate allele 
reads), alternate allele balance (minimum 20% if alternate read depth greater than or 
equal to 10 or minimum 28% if alternate read depth less than 10), and parental read 
characteristics (minimum depth of 10 reference reads; alternate allele balance less than 
3.5%). False positives were removed by in silico visualization. Of 409 case variants that 
were submitted for validation by Sanger sequencing, 394 were confirmed (specificity 
96.3%). The frequency of de novo mutations detected per proband followed an expected 
Poisson distribution in both case and control cohorts (Fig. S3). 
 
Mutational Model 
We used sequence context to derive the probability of observing a de novo variant in each 
gene as described previously (10). All protein-coding Gencode transcripts intersecting 
with target regions present on the NimbleGen v2.0 capture array and with annotations in 
the dbNSFP database were considered (26). Briefly, for each base in the exome, the 
probability of observing each of the three possible single nucleotide substitutions was 
determined. The coding consequence of each potential substitution was determined, and 
the probability of mutation was summed for each variant class (synonymous, missense, 
nonsense, essential splice site, frameshift, start lost, stop lost) and for each gene. The 
probability of a frameshift mutation was determined by multiplying the probability of a 
nonsense mutation by 1.25 as described previously (10). In-frame insertions or deletions 
are currently not accounted for by the model and were not considered in the analysis. 
Deleterious missense prediction by Meta-SVM (11) was provided by dbNSFP (version 
2.8, corresponding to a dbNSFP Meta-SVM rank score of greater than 0.83357). Where 
conflicts between two or more transcripts of a given gene occurred, the annotation 
corresponding to the longest transcript was taken. Each probability was adjusted to 
control for variable sequencing coverage as previously described: the raw probability was 
multiplied by a factor in the range 0.9 - 1, according to the percentage of trios covering 
that base with at least 10x depth. Positions with a coverage of zero resulted in a 
probability of zero for that base. The sequencing coverage adjustment was calculated 
separately for cases and controls, which were sequenced in separate batches. Each 
probability was further adjusted by a divergence score (derived from the number of 
divergent sites between humans-macaques for the gene region as well as 1MB upstream 
and downstream), as previously described (10). 
 
Statistical Analyses 
Statistical analyses were performed using R. The “denovolyzeR” package 
(http://denovolyzer.org, downloadable from the Comprehensive R Archive Network) 
implemented analyses based on the mutational model above. A detailed protocol is 
available (28).  
 
Global or gene set burden: 
Briefly, the expected number of de novo mutations in case and control cohorts across 
each variant class was determined by taking the sum of each class-specific probability 
multiplied by the number of probands in the study, multiplied by 2 (for diploid genomes). 
We tested for an excess of observed de novo mutations over expectation using Poisson 
 
 
statistics. For gene set enrichment, the expected rates were obtained from the 
probabilities corresponding to that gene set only. 
 
Number of genes with multiple de novo mutations: 
The number of genes containing multiple damaging de novo mutations was compared 
with an empirical distribution derived by permutation. The number of de novo mutations 
observed in each class was randomly distributed across all genes, weighted according to 
gene mutability. For each permutation, the number of genes with multiple mutations was 
tallied. For both cases and controls, 1 million permutations were performed.  
 
Single genes with multiple de novo mutations: 
For each gene, the expected number of de novo mutations for each class (LoF, D-Mis and 
damaging) was calculated from the corresponding de novo probability adjusting for 
cohort size. The number of de novo mutations for each gene was compared to that 
expected using a Poisson test. For each gene, we compared the number of LoF variants, 
D-Mis variants, and damaging variants (=LoF + D-Mis), using a Bonferroni corrected 
significance threshold (9x10-7, i.e.: (0.05 / (18,515 genes * 3 tests)).  
 
Percent of CHD attributable to de novo variation: 
For each phenotype under consideration (such as CHD plus both NDD and CA) the 
fraction of individuals carrying at least one damaging de novo mutation in an HHE gene 
was determined. From this rate, the expected rate of damaging de novo mutations in HHE 
genes per individual was subtracted. The expected rate was estimated by 10,000 
simulations of a cohort of 1,213 subjects harboring the expected number of mutations 
(~76; Table 1) distributed with replacement among the simulated subjects designed to 
carry an approximate Poisson distribution of mutations per person (~427 individuals 
carry 0 mutations, 448 carry 1, 235 carry 2, etc). Using this method, the expected rate 
was determined to be 0.06. 
 
Estimation of the number of risk genes: 
We followed a previously described method (7) to estimate the number of risk genes that 
are de novo mutation targets with two modifications: (a) we used our gene-specific 
background mutation rates to replace gene-size based background rates (Database S4); 
(b) we counted the number of genes mutated in two cases and three (or more) cases 
separately, and utilized such information to stabilize likelihood estimation at the lower 
range. An implicit assumption is that the penetrance of all damaging mutations in all risk 
genes is identical. 
 
We started with the number of observed damaging mutations (K) in HHE among all 
cases, the observed number of HHE genes mutated twice R1 and mutated at least three 
times R2. We set the fraction (E) of damaging mutations in risk genes based on point 
estimate of enrichment in cases compared to expectation (E = (M1 – M2)/M1, where M1 





We then estimated the likelihood of risk gene number L(G). Specifically, in the 
simulation, the number of damaging mutations (K) was fixed by the observed value in 
cases. We generated simulated mutations from two parts, i.e., risk HHE genes and 
random HHE genes. We first randomly selected G risk genes from all HHE genes with 
equal probability. We set the number of contributing damaging mutations in risk genes 
(C1) by sampling from a binomial distribution Binom(K,E), and the number of non-
contributing damaging mutations C2 = K-C1. We then simulated C1 contributing 
damaging mutations by sampling with replacement from G genes and C2 non-contributed 
mutations from all HHE genes using their background mutation rate as probability 
weights.  
 
We performed 20,000 simulations for every G from 1 to 1000, and set L(G) to be the 
proportion of simulations in which the number of genes with two damaging mutations is 




RNA sequencing on mouse hearts at embryonic day 14.5 was performed as described (6). 
For the developing brain dataset, mouse brains were harvested at embryonic day 9.5 from 
total of 36 embryos from 5 pregnant females (129SvEv background). Tissues containing 
the procencephalon, mesencephalon and metencephalon were pooled and RNA was 
extracted. RNA quality was confirmed with all RNA integrated number greater than 6.3. 
Two rounds of mRNA purification (polyA-selection) were performed on pooled total 
RNA using the Dynabeads mRNA DIRECT Kit (Life Technologies). cDNA was 
generated using the Superscript III First-Strand Synthesis System (Life Technologies) 
and cDNA libraries were constructed using the Nextera XT DNA Sample Preparation Kit 
(Illumina). Sequencing was performed to a depth of > 30 million paired-end 50-base 
reads. Reads were processed as described previously (6), and gene expression was 
calculated as fragments per kb of transcript per million fragments mapped (FPKM). Gene 
expression values are expressed as ranked centiles (Database S10; calculated for each 
heart and brain data sets) for comparison. 
 
Gene group functional profiling 
Functional gene group analysis was performed using g:Profiler (29). Genes with 
damaging de novo mutations were queried using a background gene set of Nimblegen 
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 /LVWRI GHQRYR SUREDELOLWLHV IRUHDFKYDULDQWFODVV LQHDFKSURWHLQFRGLQJJHQHRQ WKH
1LPEOHJHQ9H[RPH DGMXVWHGIRUGHSWKLQ&DVHV 3UREDELOLWLHVDUHWUDQVIRUPHGE\ log SURE
'DWDEDVH6 /LVWRI GHQRYR SUREDELOLWLHV IRUHDFKYDULDQWFODVV LQHDFKSURWHLQFRGLQJJHQHRQ WKH
1LPEOHJHQ9H[RPH DGMXVWHGIRUGHSWKLQ&RQWUROV 3UREDELOLWLHVDUHWUDQVIRUPHGE\ log SURE






'DWDEDVH6 /LVWRIYDULDQWVXQLTXHJHQHVZLWKGDPDJLQJ GHQRYR PXWDWLRQVIURPLQ
GHSHQGHQW1'' FRKRUWV   &RKRUWV 66& 6LPRQV6LPSOH[&ROOHFWLRQ Q SUREDQGV 
HSL(SLOHSWLFHQFHSKDORSDWKLHV Q SUREDQGV  GH/LJW,QWHOOHFWXDO'LVDELOLW\ Q SUREDQGV
 5DXFK,QWHOOHFWXDO'LDELOLW\ Q SUREDQGV  $6& $XWLVP6HTXHQFLQJ&RQVRUWLXP Q 
SUREDQGV  6&+,=23 6FKL]RSKUHQLD Q SUREDQGV  ''' 'HFLSHUKLQJ'HYHORSPHQWDO'LV
RUGHUV Q RISUREDQGVZLWKSXWDWLYHSDWKRJHQLFYDULDQWVDQGQR&+'  2QO\YDULDQWVRI
FODVV/R) RU'0LVE\GE16)3 0HWD690 5DQNVFRUHJUHDWHUWKDQZHUHFRQVLGHUHG &KURPR
VRPHDQGSRVLWLRQVDUHLQKJFRRUGLQDWHV $$ $PLQRDFLGLQUHIHUHQFHVHTXHQFH $$ $PLQRDFLG
LQDOWHUQDWHVHTXHQFH
'DWDEDVH6 )XQFWLRQDOWHUPHQULFKPHQWDQDO\VLVDPRQJJHQHVZLWK'DPDJLQJ/R) '0LV GH
QRYR PXWDWLRQVRYHUODSSLQJEHWZHHQ&+' FDVHVDQGWKHSXEOLVKHG1'' 31'' FRKRUW *HQHVZLWK
GDPDJLQJ GHQRYR PXWDWLRQVLQFDVHVQ JHQHVZHUHRYHUODSSHGEHWZHHQWKRVHIURPWKHH[WHUQDO
1'' FRKRUWQ JHQHV 7DEOH6WRLGHQWLI\JHQHV $QDO\VLVZDVSHUIRUPHGXVLQJJSURÀOHU
VHH0HWKRGV 3YDOXHVDUH%RQIHUURQLFRUUHFWHG
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